Johnson & Johnson outlines orthopaedics spin-off and targets 5.7% reported sales growth for 2025 amid accelerating MedTech and Innovative Medicine momentum

Earnings Call Insights: Johnson & Johnson (JNJ) Q3 2025

Management View

  • CEO Joaquin Duato highlighted “very strong third quarter results” and described Johnson & Johnson as being in a “powerful new era of growth.” The company reported operational sales growth of 5.4% and announced the planned separation

Leave a Reply

Your email address will not be published. Required fields are marked *